D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
Jonathan W. Riess,Karen Kelly,Kurt A. Schalper,M. Shimoda,S. Lim,Arta M. Monjazeb,Kathleen D. Danenberg,Elizabeth H Moore,Laurel A. Beckett,P. C. Mack,Emanual Michael Maverakis,David R. Gandara +11 more
Journal ArticleDOI
Population-based phase I trial of irinotecan and epirubicin.
Derick H Lau,Jewel Johl,Minh Huynh,Angela M. Davies,Michael Tanaka,Primo N. Lara,David R. Gandara +6 more
TL;DR: A population-based phase I trial was conducted to determine a population- based maximum tolerated dose (pMTD) for combining 2 topoisomerase inhibitors, irinotecan and epirubicin, which is recommended for conducting phase II trials.
Proceedings ArticleDOI
Abstract P2-16-05: Efficacy of ABT-888 (veliparib) in patients with BRCA-associated breast cancer
G. Somlo,Paul Frankel,T Luu,Cynthia X. Ma,Banu Arun,A. A. Garcia,Tessa Cigler,Gini F. Fleming,Harold A. Harvey,Joseph A. Sparano,Rita Nanda,H Chew,Timothy J. Moynihan,Linda T. Vahdat,MP Goetz,Arti Hurria,Joanne E. Mortimer,David R. Gandara,Alice P. Chen,Jeffrey N. Weitzel +19 more
TL;DR: This report reports on the pre-planned interim analysis of the efficacy of single agent veliparib in patients with either BRCA1 or BRCa2-associated stage IV breast cancer, and concludes that velapirib has single agent activity in both B RCA1 and BRC a2- associated stage IV Breast cancer patients, and is well-tolerated.
Book ChapterDOI
High Dose Cisplatin: Modulation of Toxicity
TL;DR: A phase II study in non-small cell lung cancer (NSCLC) concluded that a 5 day high dose cisplatin regimen resulted in a reduced incidence and severity of neuropathy and absence of severe myelosuppression, suggesting a positive clinical impact of enhanced dose intensity.